Verona Pharma (FRA:I9SA) Valuation Rank

View and export this data going back to 2018. Start your Free Trial

What is Verona Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Verona Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Verona Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Verona Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verona Pharma PLC (FRA:I9SA) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

VRNA:USA I9SA:Germany

Address

3 More London Riverside, London, GBR, SE1 2RE

Website

https://www.veronapharma.com

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.